Intravitreal combination of triamcinolone acetonide – bevacizumab (Kenacort–Avastin) in diabetic macular edema

Abstract Purpose To evaluate the effect of intravitreal injection of Triamcinolone Acetonide – Bevacizumab (Kenacort®)‐(Avastin®) in the treatment of diabetic macular edema Methods Twenty seven eyes of 17 patients with diabetic macular edema participated in this study. Each patient received an intravitreal injection of 0,1 ml triamcinolone acetonide (Kenacort®) (0,2mg)combined with bevacizumab (Avastin®) (1,25mg). Mean age was 64years and mean duration of diabetes 15,5years. The primate outcome measures were changes in best corrected visual acuity and in central macular thickness measured by OCT. The follow up period was six months from the first intravitreal therapy. Results During the follow up period 3 eyes(11%) received one, 18 eyes(67%) received two and 6 eyes(22%) received three intravitreal injections according to the monthly follow up examination. There were not observed any important complications of the intravitreal combination of Triamcinolone Acetonide – Bevacizumab either during or after the treatment. The mean visual acuity increased 0,12 (decimal) (p<0,0001) and the central macular thickness decreased 235μm (p=0,018). Conclusion Intravitreal combination of Triamcinolone Acetonide – Bevacizumab seems to be effective in improving visual acuity and macular edema in patients with diabetes.